{"id":"hydroxycamptothecin-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Gastrointestinal toxicity (diarrhea, nausea, vomiting)"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxycamptothecin is a camptothecin derivative that binds to and stabilizes the topoisomerase I-DNA complex, preventing the enzyme from completing its catalytic cycle. This leads to accumulation of DNA single-strand breaks and cell death, particularly in rapidly proliferating cancer cells. It is a semi-synthetic analog of camptothecin with improved stability and bioavailability compared to the parent compound.","oneSentence":"Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:04.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Lung cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxycamptothecin for Injection","genericName":"Hydroxycamptothecin for Injection","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells. Used for Colorectal cancer, Gastric cancer, Lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}